- Home
- DSY vs UNCY Comparison
DSY vs UNCY Comparison
Compare DSY & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSY
- UNCY
- Stock Information
- Founded
- DSY 2020
- UNCY 2016
- Country
- DSY China
- UNCY United States
- Employees
- DSY N/A
- UNCY N/A
- Industry
- DSY
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- DSY
- UNCY Health Care
- Exchange
- DSY Nasdaq
- UNCY Nasdaq
- Market Cap
- DSY 85.8M
- UNCY 74.2M
- IPO Year
- DSY N/A
- UNCY 2021
- Fundamental
- Price
- DSY $0.61
- UNCY $4.81
- Analyst Decision
- DSY
- UNCY Strong Buy
- Analyst Count
- DSY 0
- UNCY 5
- Target Price
- DSY N/A
- UNCY $41.60
- AVG Volume (30 Days)
- DSY 294.2K
- UNCY 433.9K
- Earning Date
- DSY 01-01-0001
- UNCY 11-14-2025
- Dividend Yield
- DSY N/A
- UNCY N/A
- EPS Growth
- DSY 120.37
- UNCY N/A
- EPS
- DSY 0.01
- UNCY N/A
- Revenue
- DSY $7,323,356.00
- UNCY N/A
- Revenue This Year
- DSY N/A
- UNCY N/A
- Revenue Next Year
- DSY N/A
- UNCY $19,912.34
- P/E Ratio
- DSY $49.50
- UNCY N/A
- Revenue Growth
- DSY 16.37
- UNCY N/A
- 52 Week Low
- DSY $0.58
- UNCY $3.71
- 52 Week High
- DSY $7.33
- UNCY $11.00
- Technical
- Relative Strength Index (RSI)
- DSY 28.71
- UNCY 53.58
- Support Level
- DSY $0.60
- UNCY $4.62
- Resistance Level
- DSY $0.79
- UNCY $5.39
- Average True Range (ATR)
- DSY 0.06
- UNCY 0.34
- MACD
- DSY 0.00
- UNCY -0.02
- Stochastic Oscillator
- DSY 11.96
- UNCY 45.51
About DSY Big Tree Cloud Holdings Limited Ordinary Shares
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, and sales of personal care products and other consumer goods. In particular, it is focused on the development and production of feminine pads and other feminine hygiene products. Through its platform, the company focuses on high-quality product development, deep customer engagement, and efficient sales and marketing.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.